Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Gregory Matthews | M | 73 |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 2 ans |
Cynthia Roney | F | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 11 ans |
David Tonken | M | 66 |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 2 ans |
Farran Grant | F | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 6 ans |
Bruno Jaggi | M | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | - |
Michael E. Phillips | M | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 15 ans |
Eugene T. Starr | M | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | - |
Roderick Kirkham | M | 63 |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 2 ans |
Robson Ngungu | M | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 4 ans |
John Fengler | M | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | - |
Francine Catonio | F | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | - |
Daphne Middelaer | F | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | 7 ans |
Nancy Ryan | F | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | - |
André Kindsvater | M | - |
Biomerge Industries Ltd.
Biomerge Industries Ltd. Medical SpecialtiesHealth Technology Biomerge Industries Ltd. is a Canadian medical device company and leader in fluorescence endoscopy for improved cancer detection. The Company’s first-generation product, Xillix LIFE-Lung™ received Pre-Market Approval (PMA) from the U.S. FDA in 1996. Xillix’s latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 14 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Patrick du Monceaux
- Réseau Personnel